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Abstract 
A comparison of the presentation of the polycystic ovary syndrome 
(PCOS) in adolescents compared to women aged 35 and older at 
Groote Schuur Hospital 
INTRODUCTION:  PCOS is the commonest endocrinopathy occurring in women of 
reproductive age.  This study aimed at comparing the presentation of adolescents to 
that of women ≥ 35 years presenting to the gynaecological endocrine clinic with a 
diagnosis of PCOS. 
METHODS:  This was a descriptive cohort study.  Since 1996 all women with PCOS 
have their clinical, metabolic and endocrine data entered into a database.  We 
compared the initial presentation of adolescents and  women aged 35 and above.   
RESULTS:   A total of 1549 patients were included in our database. Of these 146 
patients were ≥35 years at initial presentation and 186 were adolescents.  At  
presentation, menstrual dysfunction and acne was more common in adolescents 
than the older women (p<0.0001).  Hirsutism was a common clinical complaint both 
among adolescents (79%) and older women (77%) (NSS).  Among the older women 
55% (n=67) who had attempted to conceive complained of infertility.  The study 
population was mainly overweight or obese with only 67 adolescents and 10 adults 
having a BMI in the normal or underweight range. This tended to worsen with 
increasing age and waist hip ratio was >0.85 in 71% of adults and 46% of 
adolescents (p<0.0001).  There was no significant difference in serum testosterone 
levels and the free androgen index between the two groups.  The majority of women 
had some indication of biochemical hyperandrogenism. Most women in both groups 
had evidence of insulin resistance.  Acanthosis nigricans was more common in the 
adult women (68%) (p <0.026).  The glucose-insulin ratio was similar in the two 
groups. The majority of our patients have at least one lipid abnormality and this was 
more pronounced in the older women (P < 0.0001).  The criteria for the diagnosis of 
the metabolic syndrome was fulfilled in 31 of the adults and 12 of the adolescents. 
CONCLUSION:  Our study demonstrates that even young women presenting with 
PCOS have metabolic dysfunction. This progresses over the years and the 
metabolic disorders were more pronounced in the older women.  Early diagnosis and 
appropriate treatment of PCOS in adolescence may well improve the prognosis in 
terms of long term health. 
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Normal values and reference ranges in women: 
 
BMI      19-25kg m2 
Waist circumference   68-80cm  
WHR      <0.80      
BP      ≤120/80 
SHBG      18-144nmol/L    
DHEAS     Adolescents: 1.8-10umol/L 
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Fasting Glucose    <6.1 mmol/L 
Insulin      5-15 umol/ml 
HOMA     <2.5      
Total Cholesterol    < 5.2 mmol/L 
HDL-C     >1.6 mmol/L 
LDL-C      2.6-3.3 mmol/L 
Triglycerides     <1.7 mmol/L 
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Chapter 1: Introduction and Literature review: 
 
Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy in women of 
reproductive age, affecting 6-10% of women in the general population.1 PCOS often 
clusters in families which suggests a genetic basis to the syndrome.  
The diagnosis of PCOS is made using a combination of clinical, ultrasonographic 
and biochemical criteria. The 1990 National Institute of Health Conference on PCOS 
recommended that the criteria include evidence of hyperandrogenism and ovarian 
dysfunction but no assessment of ovarian morphology was included.2  
The 2003 ESHRE/ASRM Rotterdam consensus meeting redefined the diagnostic 
criteria for PCOS to include the presence of two out of three of the following criteria: 
1. Oligo-and/or anovulation 
2. Hyperandrogenism (clinical and/or biochemical) 
3. Polycystic ovaries on ultrasound  
Other etiologies for androgen excess including congenital adrenal hyperplasia, 
androgen- secreting tumours and Cushing’s syndrome must be excluded before the 
diagnosis of PCOS is made.2 
In 2009 the Androgen Excess Society suggested a new definition that considers 
PCOS primarily as a disorder of clinical and/or biochemical androgen excess plus 
either chronic oligo-anovulation and/or polycystic ovaries. This excludes women who 
do not have signs of androgen excess.3At present most units are using the 
Rotterdam criteria for diagnosis of PCOS and not the Androgen Excess Society 
definition. It was important that a consensus was reached with regard to the 
diagnosis of PCOS as this impacts clinical trials and audits. 
PCOS is associated with multiple metabolic abnormalities including an increased risk 
of developing impaired glucose tolerance (IGT), type 2 diabetes and gestational 
diabetes. The prevalence of IGT and type 2 diabetes is substantially higher in 
women with PCOS when compared to age and weight matched women without 
PCOS. The conversion of IGT to type 2 diabetes is accelerated in PCOS.4 
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There is a close association between obesity and PCOS. Obesity amplifies insulin 
resistance and exacerbates the development of impaired glucose tolerance and type 
2 diabetes. 5 
Women with PCOS, both lean women and those with elevated BMIs, are found to 
have an increased incidence of insulin resistance and compensatory 
hyperinsulinaemia.3 Insulin acts through multiple sites to increase endogenous 
androgen levels. Increased peripheral insulin resistance results in a higher insulin 
concentration. Excess insulin binds to the IGF-1 receptors which enhances the theca 
cells androgen production in response to LH stimulation. Hyperinsulinaemia also 
decreases the synthesis of SHBG by the liver with a resultant increase in serum free 
testosterone concentration and increased bio-availability of testosterone. 3 
Features of insulin resistance are common in women with PCOS. Hyperinsulinaemia  
is thought to contribute directly to reproductive dysfunction in PCOS.5 
Women with PCOS have increased risk factors for cardiovascular disease including 
increased body mass index, central adipose deposition, raised insulin and 
triglyceride levels, decreased HDL and increased total cholesterol and fasting LDL.16 
These risk factors are often already present at an early age in PCOS and these 
women should be monitored for early detection and appropriate intervention to 
prevent cardiovascular disease. 7 
PCO also increases risk factors for endometrial cancer through chronic anovulation 
and unopposed oestrogen stimulation of the endometrium.8 
PCOS is associated with menstrual abnormalities and is the most common cause of 
anovulatory infertility. These women have reduced ovulation rates and thus 
decreased pregnancy rates and may require treatment for infertility. 9 When 
pregnancy does occur it is often associated with higher incidence of adverse 
outcomes including gestational diabetes, fetal macrosomia, gestational hypertensive 
disorders (such as pre-eclampsia and pregnancy induced hypertension), and birth of 
small-for-gestational age babies.9  
PCOS has a negative impact on the health-related quality of life (HRQoL) in women 
with the condition. Patients with PCOS are at higher risk for developing 
psychological difficulties such as depression and anxiety and body dissatisfaction. In 
addition they are at risk for developing eating disorders and sexual and relationship 
dysfunction. 10 
Early diagnosis of the syndrome and close long-term follow-up and screening for 
diabetes and cardiovascular disease are important. There is an opportunity for 
preventative therapy, which should improve the reproductive, metabolic, and 
cardiovascular outcomes.11 
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It is recognised that adolescents who are diagnosed with PCOS may not yet have 
developed the full spectrum of the disorder and it may be important to assess them 
differently to the older woman with PCOS. 
 
Ultrasound assessment: 
Ultrasonography has widened the clinical spectrum of PCOS by its sensitivity and it 
is important to assess the ultrasound features of the ovary in all clinical presentations 
of PCOS together with the appropriate endocrine, biochemical and metabolic tests.  
Pelvic ultrasound scan should be performed by appropriately trained personnel and 
state of the art equipment is required. Transvaginal approach should be performed 
where possible and especially in obese patients unless the patient declines or in girls 
or women who are virgo intacta. Women with a regular menstrual cycle should be 
scanned in the follicular phase (days 3-5). Women with oligo-/amenorrhoeic should 
be scanned either at random or day 3-5 after a progesterone-induced bleed. If there 
is evidence of a dominant follicle > 10mm or a corpus luteum, the scan should be 
repeated in the next cycle. Calculation of the ovarian volume is performed using the 
simplified formula for an ellipsoid (0.5 x length x width x thickness). Follicle numbers 
should be estimated in both longitudinal, transverse and anterior- posterior cross 
section of the ovaries.12  
The PCO should have at least one of the following: either 12 or more follicles 
measuring 2-9mm in diameter or increased ovarian volume >10cm 3 .Only one ovary 
fitting this definition is required to define the PCO. This definition does not apply to 
women taking the oral contraceptive pill as ovary size is reduced.  
In our study the database had been reviewed and all patients fulfilled the Rotterdam 
criteria and most patients would have had polycystic ovaries and the few that didn’t 
had chemical or clinical hyperandrogenism and menstrual irregularities. 
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PCOS in adolescents compared with adult presentation: 
Adolescence according to the WHO definition includes young women between the 
ages of 10 and 19 years. Diagnosis of PCOS is more difficult in adolescents as the 
manifestations of chronic anovulation and hyperandrogenism as defined for 
diagnosis in adult women are not as easily applied in the younger age group.2 As a 
result PCOS may be underdiagnosed in the adolescent population.11 
Appropriate screening in adolescents includes a thorough family history related to 
PCOS and associated conditions, such as diabetes and hypertension as well as  
including details of menstrual irregularities, infertility, hirsuitism, alopecia, 
cardiovascular disease and PCOS in female relatives. A careful physical 
examination is central to diagnosis and signs of clinical hyperandrogenism and 
insulin resistance should be documented.  
Clinical markers of hyperandrogenism are present in two thirds of adolescents with 
PCOS.13,14 These include hirsutism which is defined as terminal, coarse, dark hair on 
the face, back, abdomen, chest and inner thighs (scored using the Ferriman- 
Gallwey scoring system), acne (which is commonly seen during the adolescent 
years) or alopecia. In many adolescents the more convincing signs and symptoms of 
androgen excess often may not have yet developed at the time of initial 
presentation.14,15 
The third Rotterdam criterium for diagnosis of polycystic ovaries on ultrasound is less 
applicable in adolescence as transabdominal scans are often performed rather than 
transvaginal scans and the resolution may be suboptimal, especially if the patient is 
obese. “Multicystic” ovarian morphology is often a feature of puberty and represents 
recruitment of multiple follicles without the selection and development of a dominant 
follicle and subsides with the onset of regular menstrual cycles and should not be 
confused with features of polycystic ovaries.15 It is recognised that while 
transabdominal scans have limitations, the presence of large volume ovaries (10ml 
or greater) regardless of the resolution may, together with the clinical presentation, 
contribute to the Rotterdam diagnostic criteria. 
Early diagnosis and intervention in young women potentially may prevent many of 
the long-term health consequences associated with PCOS.13,16 
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Obesity and PCOS: 
Obesity has serious health implications and is associated with increased risk of 
psychosocial impairment, Type 2 diabetes, cardiovascular disease and uterine 
cancer.16,17 Obesity is classified using body mass index (BMI) where a BMI > 25 is 
overweight and a BMI> 30 is obese. Another practical tool is waist –hip ratio and a 
ratio >0.85 in women indicates central adipose deposition and an increased risk for 
cardiovascular disease. 
There is a close association between obesity and PCOS and a history of weight gain 
frequently precedes the onset of hyperandrogenism.18  Fifty percent or more of adult 
women with PCOS have a body mass index over 30 (this varies between 
populations). Visceral or central fat is associated with a more adverse metabolic risk 
profile than subcutaneous fat and the prevalence of metabolic syndrome increases 
with obesity.  
Obesity worsens the clinical manifestations of PCOS by increasing insulin 
resistance, decreasing the production of SHBG in the liver which impacts the 
bioavailability of testosterone and therefore potentiates the androgen manifestations 
of the syndrome. 18 Given the current epidemic of childhood obesity, early and 
accurate diagnosis of PCOS is vital as obesity increases the chances of associated 
metabolic and cardiovascular morbidities.19 
The fat distribution in PCOS tends to be visceral or central even in lean patients and 
this is associated with greater insulin resistance which exacerbates the metabolic 
abnormalities of PCOS and increases the risk of developing Type 2 diabetes and the 
risk of cardiovascular disease. 21 
Lean PCOS patients may present with a different biochemical phenotype, with more 
androgen excess and less insulin resistance than obese PCOS patients. 22 In a study 
done at Columbia University (USA) in 2003 comparing 48 adolescents divided into 
three groups including 11 non obese PCOS adolescents, 22 obese adolescents with 
PCOS and 15 obese controls it was found that there is a more pronounced alteration 
in the hypothalamic-pituitary-adrenal axis in non-obese adolescents with PCOS and 
a more marked disregulation of insulin levels and impairment of insulin sensitivity in 
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their obese counterparts. Non obese adolescents had higher levels of LH, SHBG, 
DHEAS, androstenedione, dihydrotestosterone, free IGF-I and HDL and lower levels 
of LDL whereas obese PCOS adolescents had higher levels of fasting insulin and 
proinsulin and fasting glucose to insulin ratio.22 
Insulin Resistance and PCOS: 
About one third of overweight or obese women with PCOS have either impaired 
glucose tolerance or type 2 diabetes by the age of thirty.23In 2007 the Androgen 
Excess Society position statement recommended that all patients with PCOS should 
be screened for IGT with a two hour oral glucose tolerance test and those with IGT 
should be screened annually for development of type 2 diabetes.24 Family history of 
diabetes, increased BMI, and a history of GDM is associated with an increased risk 
of glucose intolerance in women with PCOS.4 
Hyperinsulinaemia plays a role in the hyperandrogenism of PCOS by stimulating 
androgen production in the theca cells of the ovary and indirectly by suppressing 
hepatic synthesis of sex hormone binding globulin (SHBG) which leads to increased 
tissue availability of circulating testosterone.25  
There is a high frequency of IGT and NIDDM among women with PCOS and insulin 
resistance is a risk factor for type 2 diabetes. In a study done in Adelaide (Australia) 
in 2001 assessing 67 women with PCOS there was shown to be a high incidence of 
adverse change in glucose metabolism and over a period of 6.2 years 54% of 
women with IGT at baseline developed NIDDM.26  
Clinical surrogates for insulin resistance include truncal obesity, skin tags and 
acanthosis nigricans which is a velvety rash, on the back of the neck, axilla and groin 
and is a cutaneous manifestation of insulin resistance.20 
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Metabolic syndrome and PCOS: 
Adolescent girls with PCOS have a 4.5 times increased risk of developing metabolic 
syndrome compared with the general adolescent population.3,25 One third of 
adolescents with PCOS meet criteria for metabolic syndrome. 19 Metabolic syndrome 
is associated with insulin resistance, glucose intolerance, dyslipidaemia, 
hypertension and central obesity. 25 In a study done in the USA at Yale University by 
Weiss and his co-workers reviewing the metabolic syndrome in adolescents the 
prevalence of metabolic syndrome was high amongst obese children and 
adolescents and increased with the severity of obesity reaching close to 50% in 
severely obese adolescents. 19,26 
Those PCOS phenotypes with the combination of hyperandrogenism and 
oligomenorrhea are most at risk for developing metabolic syndrome. 17 It is important 
that once the diagnosis of PCOS has been made in an adolescent girl, she should 
be followed up long term and regularly screened for metabolic abnormalities.19 
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Table 1: Criteria for the diagnosis of metabolic syndrome in adult women with 
PCOS requires 3 out of 5 criteria.20 
Risk Factor Cut Off 
1. Abdominal obesity (waist 
circumference) 
>88cm  
2. Triglycerides > 1.695mmol/L 
3. HDL-C < 1.295mmol/L 
4. Blood pressure ≥130/≥85 mm Hg 
5. Fasting and 2 hour glucose from 
OGTT 
Fasting:6.105-6.993mmol/L 
2 hour glucose: 7.77-11.0445mmol/L 
 
The diagnostic criteria for metabolic syndrome in adolescents were modified from the 
adult criteria by lowering the TG and HDL cutoff points and using the 90th percentile 
for age, gender, and height for blood pressure as cutoff points.25 This takes into 
account the fact that many of the abnormalities worsen with age and the adolescent 
may therefore initially be less affected than her older counterpart. 
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Table 2: The recommended diagnostic criteria for metabolic syndrome in 
adolescents: three out of five of these criteria must be present.26 
Risk Factor Cut-off 
1. Waist circumference >90th percentile for age and sex 
2. Triglycerides >1.24mmol/L 
3. HDL-C <1.036 mmol/L 
4. Blood Pressure >90th percentile of age and sex 
5. Fasting blood glucose >5.55 mmol/L 
 
Hyperandrogenaemia, in addition to obesity and insulin resistance, is an important 
risk factor for metabolic syndrome and it is thought that early identification of 
adolescent girls with PCOS and metabolic syndrome may allow early intervention to 
decrease the metabolic effects such as the risk of developing diabetes and 
cardiovascular disease.25 Levels of LDL cholesterol and triglycerides have been 
shown to be higher and HDL lower in adolescents with PCOS compared with 
unaffected adolescents and when left untreated the abnormalities continued to 
worsen.7  
 
 
Hyperandrogenism in adolescents with PCOS: 
Hyperandrogenism is seen clinically as acne, hirsuitism, male pattern balding, diffuse 
alopecia, seborrhoea or hyperhidrosis.14 Hirsuitism is seen in two thirds of 
adolescents with PCOS and is graded with the Ferriman Gallwey scoring system 
with a score of 8 or more indicating hirsuitism.52 The hirsuitism of PCOS is often 
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slowly progressive and adolescents may not yet have developed clinically significant 
symptoms.3 
The history of hirsuitism should include the timing, location, and rate of progression 
and recent changes in the amount of hair. It is also important to ask about methods 
used to remove unwanted hair including shaving, waxing, bleaching, electrolysis and 
laser hair removal and how this changes after treatment is initiated.  Although 
testosterone is the biochemical marker that is frequently used to define 
hyperandrogenism it is recognised that this is not an accurate reflection of 
bioavailable androgens.14 The free androgen index (which is calculated) as 
testosterone (nmol/l) × 100 ÷ SHBG (nmol/l) gives a better indication of  
bioavailability. 
 
Menstrual Disturbances: 
Menstrual dysfunction is seen in two thirds of adolescents with PCOS and includes 
primary/secondary amenorrhoea, oligomenorrhoea, dysfunctional uterine bleeding 
and anovulatory regular menses.3 Menstrual irregularities are common in unaffected 
women in the years following menarche and up to 85% of menstrual cycles are 
anovulatory in the first year following menarche and 59% are still anovulatory three 
years after the onset of menarche. 17 
 
 
 
Quality of life in adolescents with PCOS: 
Symptoms of PCOS develop around menarche including acne, weight gain, 
hirsuitism and menstrual problems and have been shown to have a negative impact 
on quality of life of affected adolescents in a health related quality of life study. 
Adolescents with PCOS often have low self-esteem, self-consciousness, poor body 
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image and struggle with weight control. Anorexia, depression and anxiety in 
adolescents has been linked to PCOS.28  
 
Treatment: 
Untreated PCOS is a progressive syndrome and there is a need for early diagnosis, 
intervention and treatment including lifestyle modification and weight 
loss.27Treatment is aimed at the underlying pathophysiology and the presenting 
symptoms of the patient.3 
Goals of treatment include management of irregular menses, protection of the 
endometrium from unopposed oestrogen stimulation (and development of 
endometrial hyperplasia and endometrial), decrease in hirsuitism and acne, 
decrease in the risk of developing diabetes mellitus or dyslipidaemia and improved 
quality of life.29 
1. Life style modifications: 
Even modest weight loss of 5-10% of body mass has been shown to improve the 
impact of PCOS and improve menstrual function .30 A serious attempt at weight loss 
is first line treatment for overweight or obese adolescents with PCOS. Lifestyle 
modifications with weight loss and exercise have been shown to decrease the 
incidence of diabetes even more effectively than when using metformin therapy.31 
Weight loss decreases the circulating androgen levels and decreases serum 
testosterone and increases SHBG and, as a consequence, decreases free androgen 
index.34  
 
2. Oral Contraceptive Agents: 
The oestrogen in the COC suppresses LH and thus ovarian androgen production 
and increases hepatic production of SHBG. This results in less free testosterone.2 
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Usually a combined oral contraceptive that provides 30 to 35 micrograms of ethinyl 
estradiol is used cyclically, is tricycled or is given continuously.28 
 
3. Progestins: 
Cyclical progestins can be used to provide regular menses and endometrial 
protection but they do not treat the insulin resistance or the androgen excess 
effectively.2 
4. Anti-androgens: 
A range of antiandrogens can be used to control hair growth and are often used with 
COC’s. Spironolactone, an aldosterone antagonist, is used in USA for its 
antiandrogen properties. In a Cochrane review it was shown to improve hirsuitism 
and decrease the Ferriman-Gallwey score.29 Spironolactone is usually used in 
combination with a combined oral contraceptive preparation. A Cochrane review in 
2003 comparing the effectiveness of cyproterone acetate with or without ethinyl 
estradiol with other anti-androgens found that cyproterone acetate when combined 
with estradiol caused a subjective improvement in hirsuitism and has similar 
beneficial effects to other anti-androgenic agents.30 
5.Insulin Sensitizing Agents: 
Treatment with insulin sensitizing agents such as metformin in adolescents and adult 
women improves ovulatory dysfunction, hyperandrogenemia, insulin resistance and 
possibly hirsuitism as well as decreasing total cholesterol, triglycerides and LDL 
cholesterol.30 
PCOS remains a challenge and requires management throughout reproductive life. 
A major impact on long term health is seen in older women and in theory if 
management is started in adolescence it may prevent the long term sequelae 
associated with PCOS. 
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Objectives: 
The purpose of this study is to compare adolescents with PCOS with women aged 
35 years and upwards who presented for the first time to the Gynaecological 
Endocrine clinic at Groote Schuur Hospital with PCOS and to compare the 
presentation, metabolic and endocrine profiles of the two groups.  
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Chapter 2: Methodology and study design: 
This is a descriptive cohort study. The study population were patients who presented 
to the Gynaecological Endocrine Clinic with a diagnosis of PCOS as defined by the 
Rotterdam 2003 criteria and entered into our database, with their consent.  
Inclusion criteria:  
 Consent to be included in the PCOS database at first presentation. 
 Any adolescent women presenting to the Gynaecological Endocrine Clinic 
with a diagnosis of PCOS. 
 Women who presented at 35 years of age and older with a diagnosis of 
PCOS. 
Exclusion criteria: 
 Any women in our clinical service who declined to have their information 
included in the PCOS database.  
Recruitment and enrolment: 
Patients have prospectively been entered into the PCOS database since 1996 and 
their data were reviewed. Of the 1549 patients recorded in the database to date, 183 
are adolescents and 146 presented at 35 years or older. At presentation to our clinic 
a detailed history was taken, which included enquiry into menstrual patterns, 
reproductive function, signs of clinical hyperandrogenism (hirsuitism and acne), 
personal and family medical history, the use of any medication, contraceptive use 
and past treatments for PCOS. 
All subjects underwent a physical examination including, weight, height, waist and 
hip circumference, assessment for clinical features of hyperandrogenism, hirsuitism 
and hyperinsulinaemia (acanthosis nigricans). Blood for endocrine and metabolic 
assessment was taken after an overnight fast. 
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Information entered into the database includes: 
 Age 
 Ethnic Group 
 Height and weight and BMI (kg/m2) 
 Waist-Hip ratio 
 Menstrual history 
 Hirsuitism and acne 
 Fertility problems 
 Presence of acanthosis nigricans 
 Blood pressure (mmHg) the mean of three readings taken in recumbent 
position 5 minutes apart 
The database includes the results of fasting blood samples: 
 FSH, LH, Estradiol 
 Testosterone, DHEAS, 17α OHP 
 SHBG 
 Glucose, Insulin 
 Lipid profile including cholesterol, triglycerides, HDL and LDL 
 FAI calculated 
 Glucose:insulin ratio calculated 
 HOMA (calculated using the following formula: HOMA= [Insulin (uU/ml) × 
Glucose (mmol/L)] ÷ 22.5.  
The endocrine profile was not assessed in women using hormonal treatment at the 
time of assessment. If this was considered essential, hormone therapy was stopped 
for 4 weeks in the case of the COC and longer after injectable progestogens before 
assessment. The reference ranges for testosterone and FAI changed in July 2010 
and because of this testosterone was recorded either as raised or not raised rather 
than giving a value. 
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Data Safety and monitoring: 
The data is anonymized and strict confidentiality is maintained and only the research 
team has access to the database. 
 
Data Analysis: 
Clinical data recorded from the clerking sheets by members of the Reproductive 
Medicine Unit were captured using Microsoft Excel and was entered into our PCOS 
database by members of our research team. For this subanalysis data was 
extrapolated for adolescents and women 35 years and older. 
Statistical analysis was performed with assistance from Katya Mauff a statistician 
from the department of Statistical Sciences at the University of Cape Town. 
Informed consent: 
Informed consent or assent in underage women was taken when the patients 
presented to the Gynaecology Endocrine Clinic. Subsequently the Human Research 
Ethics Committee has given us permission to maintain the database, provided 
patients are informed about the addition of new data. 
Research Ethics Committee Approval: 
Approval to undertake this sub analysis was granted by the Human Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town. (HREC 
REF 085/1996 & 068/2009) 
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Chapter 3: Results 
Summary demographics for study population: 
From 1996 until 2013, a total of 1549 patients were included in the PCOS database 
of these 146 patients were 35 years or older and 183 were between the ages of 10 
and 19 years old. The clinical data was collected and captured using Microsoft excel. 
The mean age of the older women was 37± 3.0 (35-46) and of the adolescents was 
17 ± 2.0 (12-19). The majority of the patients were of coloured ethnicity 86% of the 
adolescents (n=161) and 84% (n=122) of the older women were from this ethnic 
group. 
BMI: 
Many of the study population was overweight and the majority had an increased BMI 
but there was a statistically significant difference in BMI between the two groups. 
The older women were more likely to be overweight or obese the mean BMI being 
35.7± 7.5 (19.9-53.6) and BMI for the adolescent group was 29.4± 8(16.4-60.9). Only 
6.8% (n=10) of the older women had a normal BMI compared with 32.2% (n=67) of 
the adolescent group. 
Table 3: BMI 
 
 
Group 
Total Adolescent Adult 
BMI Underweight 7 0 7 
Normal 60 10 70 
Overweight 33 28 61 
Obese 66 67 133 
Obese Class 3 ⃰ 20 41 61 
Total 186 146 332 
χ2= 16.786 df1 , p<0.0001 ( ⃰Obese class 3 = BMI ≥ 40) 
 
P a g e  | 27 
 
Waist-hip ratio: 
The mean waist hip ratio was 0.9 ± 0.1 in both the women aged 35 years and older 
and the adolescents. But a greater proportion of the older women 71.3% (n=102)  
compared to 46.2% (n=84) of adolescents had a waist-hip ratio greater than 0.85.  
Table 4: Waist- hip ratio 
 
 
Group 
Total Adolescent Adult 
WHR WH<=0.85 98 41 139 
WH>0.85 84 102 186 
Total 182 143 325 
χ2 = 20.735 df1, p < 0.001. 
Blood Pressure: 
The mean blood pressure in the adult group was 128/78mmHg and in the adolescent 
group was 116/69 mmHg. The prevalence of hypertension as defined as having a  
systolic blood pressure greater than 140mmHg and diastolic blood pressure greater 
than 90mmHg was 28% (n=41)  in adult group and 8% (n=15) in the adolescent 
group. (χ2= 23.3741, df1, p<0.0001.) 
Table 5: Blood Pressure 
Crosstab 
Count   
 
Group 
Total Adolescent Adult 
BP <140/90 179 116 295 
≥140/90 15 41 37 
Total 186 146 332 
 
Forty adolescents (21.5%) and 73 (50%) of adults had a systolic blood pressure 
greater than 130mmHg and a diastolic blood pressure greater than 85. Which is the 
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cut-off for BP as a criterium for diagnosing the metabolic syndrome. (χ2= 29.580, df1, 
p< 0.0001). More of the older women had demonstrated a blood pressure in the 
range for diagnosis of the metabolic syndrome. (see table 6) 
Table 6: Blood Pressure for the diagnosis of Metabolic Syndrome 
BP≥(130/85) Over 35 
Under 
20 Total 
<130/85 73 146 219 
≥130/85 73 40 113 
Total 146 186 332 
 
Menstrual cycle: 
Menstrual irregularities were reported in 167 (89.7%) adolescents at recruitment and 
105 (72.4%) of women 35 years and older. There is a statistically significant 
difference between the two groups. In both groups oligomenorrhoea was the 
commonest menstrual abnormality reported by 48.9% (n=71) of older women and 
47.3% (n=88) of the adolescents. In the adolescent group only 10.2% (n= 19) 
reported a regular menstrual cycle whereas in the older women 27% (n=40) reported 
a regular menstrual cycle. 
Table 7: Menstrual cycle 
 
 
Group 
Total Adolescent Adult 
Menstrual 
cycle 
Prim Amen 5 0 5 
Sec Amen 42 19 61 
Oligomen 88 71 159 
Regular 19 40 59 
Irregular 26 10 36 
Menorrhagia 5 2 7 
Other 1 3 4 
Total 186 145 331 
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Table 8: Menstrual cycle dysfunction  
 
 
Group 
Total Adolescent Adult 
Menstrual dysfunction 
Regular cycle    
167 105 272 
19 40 59 
Total 186 145 331 
χ2 = 16.786 df 1, p< 0.0001 
Clinical Hyperandrogenism: 
1.Hirsuitism: 
The presence of hirsutism or unwanted hair was a common presenting problem in 
both groups. There was no significant difference noted between the two groups. 
Hirsutism either mild, moderate or severe was reported in 79.3% (n=146) of the 
adolescents and in 76.6% (n=109) of the adults. 
 
 
 
 
 
 
Table 9: Hirsutism 
 
 
Group 
Total Adolescent Adult 
Hirsutism Nil 38 37 75 
Mild 71 47 118 
Moderate & Severe 75 62 137 
Total 184 146 330 
χ2= 1.776 df2, p=0.411 
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2.Acne 
Acne was seen more commonly in the adolescent group, 107 (57%) had some 
degree of acne. In this group mild acne was present in 36.5% (n=68) of the 
adolescents and moderate and severe acne in 20.9% (n=39) whereas in the group of 
women aged 35 years and older only 29.8% (n=43) of women had either mild, 
moderate or severe acne and 70.1% (n=101) had no acne documented. There was a 
significant difference between the two groups (χ2= 25.056, df1, p<0.0001). 
Fertility 
In the adolescent group only 13(6.9%) patients had attempted to conceive and of 
these only 5 (38.4%) had been successful. In the women 35 years and older 
123(84.2%) had attempted fertility and of these 67 (54.5%) reported that they had 
problems conceiving with 31 (25.2%) reporting primary infertility and 36 (29.2%) 
reporting secondary infertility. 
Table 10: Fertility 
 
Group 
Total Adolescent Adult 
fert1 Attempted 13 123 136 
Never Attempted 173 23 196 
Total 186 146 332 
 
 
 
Table 11: Primary versus Secondary Infertility 
 
 
 
Group 
Total Adolescent Adult 
FERTILITY Primary Infertility 8 31 39 
Secondary Infertility 0 36 36 
Total 8 67 75 
χ2= 8.266, df1, p= 0.004. 
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Metabolic parameters: 
There was no significant difference in the mean fasting insulin level, HOMA and 
glucose: insulin ratio between the two groups. In older women the mean fasting 
insulin was 23.9 mmol/L and in adolescent group it was 24.4mmol/L. This is raised in 
both groups as normal fasting insulin is usually around 5mmol/L. HOMA-IR is an 
evaluation of insulin resistance by analysing fasting glucose and insulin levels in the 
blood. A HOMA score > 2.5 is an indication of insulin resistance and this was found 
in 114(78%) of the older women and 129(69.3%) in the adolescent group ( χ2= 
3.175, df1, p=0.075). Mean HOMA score in the older women was 6.6 ± 6.4 and in the 
adolescents HOMA score was 5.9 ± 8.2. (NS) 
 
Table 12: HOMA 
 
 
Group 
Total Adolescent Adult 
homa HOMA<=2.5 57 32 89 
HOMA>2.5 129 114 243 
Total 186 146 332 
 
A glucose:insulin ratio of < 0.45 indicates insulin resistance. This was low in both 
groups. In both the adult group 74.8% (n=107) and the adolescent group 78.8% 
(n=145) had a low G:I ratio less than 0.45. (χ2= 0.721, df1, p=0.396 (NS) 
Table 13: GI-ratio 
 
Group 
Total Adolescent Adult 
girat GIratio>=0.45 39 36 75 
GIratio<0.45 145 107 252 
Total 184 143 327 
 
P a g e  | 32 
 
Normal fasting glucose measurement  should be between 4-6mmol/L and in the 
older women this was raised, the mean fasting glucose in adult women was 6.0 
mmol/l compared to 5.0mmol/l in adolescent women (normal range). 
The clinical feature of hyperinsulinaemia including trucal obesity and acanthosis 
nigricans were seen more frequently in adult women compared to adolescents, with 
67.8% (n=97) of adult women and only 55.7% (n=102) of adolescents presenting 
with acanthosis nigricans. (χ2= 4.938. df1, p=0.026). 
 
 
Table 14: Acanthosis Nigricans: 
 
 
Group 
Total Adolescent Adult 
ACANNIG Yes 102 97 199 
No 81 46 127 
Total 183 143 326 
 
Endocrine changes 
Serum Androgens: 
There was no statistically significant difference in testosterone levels or free 
androgen index between the two groups. In the adolescent group 76.7% and in the 
adult group 82.5% had raised testosterone levels. (χ2= 1.595, df1 , p=0.207).  
Table 15:Testosterone 
 
 
Group 
Total Adolescent Adult 
testo NOT RAISED 42 25 67 
RAISED 139 118 257 
Total 181 143 324 
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Free androgen index is calculated by total testosterone× 100/ SHBG and this value 
gives an indication of the bioavailable testosterone level. Slightly more of the older 
women 39% (n=55) had a raised FAI compared with 30% (n=54) of the adolescent 
group. (χ2= 3.443, df1, p=0.064 NS).  
Table 16: FAI 
 
 
Group 
Total Adolescent Adult 
FAI NOT RAISED 128 84 212 
RAISED 54 55 109 
Total 182 139 321 
SHBG: 
SHBG may be low in women with PCOS. Normal range for SHBG in both age 
groups is 18-144nmol/L, in the adolescent group 28.5% (n=53) and in the adult 
group 17% (n=25) had SHBG levels less than 18 nmol/L.( Χ2=  5.3398, df1,  P = 
0.021) 
 
Table 17: SHBG 
 
SHBG Over 35 
Under 
20 Total 
>=18 115 130 245 
<18 25 53 78 
Total 140 183 323 
 
DHEAS: 
DHEAS may be raised in PCOS as a result of increased adrenal androgen 
production. In unaffected populations the normal range for adolescents is 1.8-10 
umol/L and in adults is 1.7-9.2 umol/L. DHEAS and 17α-OHP in our study was only 
recorded after 2008 and therefore there are no values available from 1996 to 2008. 
Using the available data it was found that 14% (n=5 out of 36) of the older women 
and 18% (n=15 out of 81) of the adolescents had elevated DHEAS levels. (Χ2 =   
0.3769, df 1, p = 0.539) (NS). 
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Table 18: DHEAS 
 
 
 
 
 17- α-Hydroxy Progesterone 
Normal range for 17- OHP for both groups is 0.7-14.2nmol/L. In this study there are 
only 17-OHP values available for 33 women older than 35 and 78 adolescents.  We 
found that 17-OHP was only increased in 3.8% (n=3 out of 78) of the adolescents 
and 3% (n=1 out of 33). Pearson (χ2=   0.0444, df1 ,  p = 0.833) (NS) 
 
Table 19: 17α-OHP 
17-OHP Over 35 
Under 
20 Total 
outside 
norm 1 3 4 
norm 32 75 107 
Total 33 78 111 
 
Serum Lipids 
Serum total cholesterol, LDL cholesterol and triglyceride levels were significantly 
higher in the adult group than the adolescents. In the adult group 13.7% (n=20) of 
women the values of all four lipids were abnormal compared with 3.2% (n=6) of 
adolescents. In the adult group only 17.8% (n=26) had no lipid abnormalities 
compared with 41.2% (n=77) of adolescents. 
Mean cholesterol level in adults was 5.1mmol/L ± 1.0 versus 4.6mmol/L ± 0.9 in 
adolescents. In the adult group 48 (33.5%) compared with 30 (16.6%) adolescents 
DHEAS Over 35 
Under 
20 Total 
Raised 5 15 20 
Norm 31 66 97 
Total 36 81 117 
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had a triglyceride level greater than 1.5mmol/L. HDL-C was lower in the adult group 
than the adolescents and 66.3% (n=120) of adolescents versus 53.2% (n=75) of 
adults had an HLD-C level greater than 1.2 mmol/L. 
 
Metabolic syndrome: 
The prevalence of metabolic syndrome in the adolescent group was 12.7% (n=23) 
when applying the adult criteria. There is no difference in prevalence of metabolic 
syndrome when the criteria for diagnosing metabolic syndrome in adolescents was 
used. In the adult group 37% (n=54) of women met the criteria for metabolic 
syndrome. This difference is statistically significant (χ2= 28.527, df1, p<0.001). 
 
Table 20: Adult criteria for metabolic syndrome: 
 
 
 
 
Group 
Total Adolescent Adult 
Adult Criteria Criteria not satisfied 158 87 280 
Criteria satisfied 23 54 43 
Total 180 143 323 
 
Table 21: Adolescent criteria for metabolic syndrome: 
 
 
 
   
 
Group 
Total Adolescent 
Adolescent Criteria not satisfied 157 157 
Criteria satisfied 23 23 
Total 180 180 
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Summary of results 
Group Women 35 years and older Adolescents 
Total number studied N=146 N=186 
Age (mean±SD) 37 ±3.0 17±2.0 
BMI (mean±SD) 35.7±7.5 29.4±8.0 
WHR (mean± SD) 0.9±0.1 0.9±0.1 
Systolic BP (mean±SD) 128±17.0 116±14.0 
Diastolic BP (mean±SD) 78.0±11.0 69.0±9.0 
          SHBG (mean±SD) 34.6±23.6 37.1±34.0 
DHEAS (mean±SD) 4.7±2.5 6.3±2.9 
17α-OHP (mean±SD) 4.8±3.8 6.6±4.5 
Fasting Glucose (mean±SD) 6.0±2.3 5.0±1.3 
Fasting Insulin (mean±SD) 23.9±18.4 24.4±21.6 
HOMA (mean±SD) 6.6±6.4 5.9±8.2 
Total Cholesterol (mean±SD) 5.1±1.0 4.6±0.9 
Triglycerides (mean±SD) 1.6±1.2 1.1±0.9 
HDL-C (mean±SD) 1.3±0.3 1.4±0.4 
LDL-C (mean±SD) 3.0±1.0 3.0±1.0 
Total with menstrual dysfunction N=105 (72.4%) N=167(89.7%) 
Total with hirsutism N=109(76.6%) N=146 (79.3%) 
GI-ratio< 0.45 N=107 (74.8%) N=145(78.8%) 
Acanthosis Nigricans present N=97 (67.8%) N=102(55.7%) 
Raised Testosterone N=118 (82.5%) N=139 (76.7%) 
Raised FAI N=55 (39%) N=54(30%) 
Metabolic Syndrome  N=54 (37%) N=23 (12.7%) 
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Chapter 4: Discussion 
This study demonstrates that even young women with PCOS have signs of 
metabolic dysfunction and this seems to progress over time and is more pronounced 
in the older women. 
The study population was mainly overweight and in the adolescent group 63.9% 
were classified as overweight, obese or obese class 3 compared to 93% of older 
women. This is higher than the numbers reported by Balen et al in the UK where 
40% of their study population were overweight  and in Amsterdam in the Netherlands 
Elting et al found that 44% of 300 women with PCOS had a BMI>25.35,36 In a report 
from New York City Dunaif et al reported obesity rates of 66% in women with 
PCOS.37  
Obesity tended to worsen with increasing age and the mean waist: hip ratio among 
the adolescents in our study was 0.9± 0.1. This was greater than the mean hip waist 
ratio reported by Mastorakos et al in Athens, which was 0.77 ± 0.02 in their 
adolescent group.44 Huang et al reported a mean waist hip ratio of 0.8 in their study 
population in South China.45  A waist: hip ratio > 0.85 indicates central obesity and a 
visceral distribution of adiposity putting these women at increased risk of 
cardiovascular disease. 
Weight loss has been shown to have beneficial effects in improving menstrual cycle 
frequency, restoring ovulation and normalising biochemical indices especially insulin 
resistance. 31Pasquali et al studied 20 obese hyperandrogenic women and showed 
that after weight reduction, insulin values in the OGTT were lower and similar to that 
reported in normal-weight women. 38. A study from Adelaide, Australia by Clark et al 
reviewing 67 women with PCOS who lost an average of 10.2kg± 4.3kg, reported that 
60 out of 67 women who were previously anovulatory, resumed ovulation after 
weight loss and 52 of the 67 women achieved pregnancy.39 Early life style 
interventions in the adolescent group and targeting weight loss is vital in reducing 
androgen excess and improving reproductive functioning.3 
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Our study showed that at presentation, menstrual dysfunction was very common in 
the adolescent group, seen in 89.7% of the adolescent group and 72.5% in the older 
women. This is higher than the rates suggested by Hickey et al from Melbourne, 
Australia who reported menstrual irregularities in 51% of their adolescent PCOS 
population and Carmina et al who reported menstrual abnormalities in 40-50% of 
adolescents in their study.32, 15 
Hirsuitism is a clinical indicator of androgen excess and was a common clinical 
complaint both among adolescents (79%) and older women (77%) which is higher 
than that reported by Warren-Ulanch et al in their study, where hirsuitism was 
present in two thirds of adolescents with PCOS and Azziz et al reported hirsuitism in 
approximately 60% of adult women.2,40 
Acne was not a common presenting complaint among the adult women with only 
30% presenting with acne compared to 57% in the adolescent group. This suggests 
that acne maybe a transient occurrence associated with puberty and not a reliable 
sign of androgen excess. 
In our study serum testosterone was raised in many of the patients but there was no 
significant difference in the testosterone levels between the two groups. 
Measurement of FAI is a better indication than total testosterone of the bioavailability 
of testosterone and was raised in a greater percentage of the adult women (40%) 
compared with (30%) of the adolescent group.  
DHEAS was raised in more of the adolescent (18%) compared to the older women 
(14%) and this is lower than expected Azziz et al reported that approximately 20-30 
% of patients will demonstrate elevated levels of DHEAS and in 10% of patients this 
may be the sole abnormality of circulating androgens.53 DHEAS and FAI data was 
incomplete and so we cannot draw a conclusion from these results. 
Insulin resistance plays an important role in the pathogenesis of PCOS and evidence 
of insulin resistance is seen in both groups. In our study the incidence of insulin 
resistance with HOMA > 2.5 was 78% in older women and 69% in the adolescent 
group and this is higher than numbers reported by Begum in a study done in South 
East Asia where only 43% of the adult women had raised HOMA levels.42  Studies in 
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the USA by Ehrman et al show that the prevalence of IGT and NIDDM is higher in 
women with PCOS when compared to age and weight matched controls and report 
that 45% of women with PCOS in their study had an abnormal OGTT with an 
incidence of IGT in these women of 35% and NIDDM in 10% of women .41  
Acanthosis nigricans is a marker of insulin resistance and was seen more commonly 
in the older group (68%) (p<0.026) this is in keeping with the rate of acanthosis 
nigricans reported by Sharquie et al of 64% amongst women with PCOS presenting 
with primary infertility in Bagdad, Iraq.43  The glucose-insulin ratio was similar 
between the adolescents and older women (p= 0.396).  
Serum SHBG is a surrogate marker of androgen dynamics and levels are often lower 
in women with PCOS due to decreased liver production under the influence of 
hyperinsulinaemia. In our study there was a significant difference between the two 
groups with a greater percentage of the adolescents having low SHBG level despite 
the finding that insulin resistance and a HOMA score >2.5 were more common in the 
adult population.  
Our study shows that insulin resistance is a core component of PCOS and is present 
from early on in the disease process. Affected adolescents are at increased risk of 
developing impaired glucose tolerance and type 2 diabetes. A study by Norman et al 
over 6.2 years demonstrated that the change in glycaemic control from baseline is 
frequent and 9% of patients who were normoglycaemic at baseline developed IGT 
and 8% moving from normoglycaemia to NIDDM and of the patients with IGT at 
baseline 54% had progressed to NIDDM at follow up.26  
Lewy et al showed that correction of hyperinsulinaemia in adolescents with PCOS 
either through weight loss or pharmacological treatments, possibly a combination of 
metformin and the COC, is indicated in the women with insulin resistance, this leads 
to lowering of the androgen levels and improvement of ovulatory function and may 
delay the progression to type 2 diabetes.54  
In our study there were more older women who had insulin resistance but this was 
not statistically significant despite the fact that more of the older women had 
increased BMI. Obesity influences the development of insulin resistance but there 
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are other contributing factors. Up to 75% of lean PCOS patients are found to have 
insulin resistance. Possibly women who presented in adolescence may have had 
more severe metabolic disturbances typical of PCOS leading to their early 
presentation and this may have been influenced by genetic factors.26 
PCOS is the most common cause of anovulatory infertility. In our study 54% of the 
older women who had attempted fertility, reported either primary infertility (25%) or 
secondary infertility (29%). In the adolescent group of the thirteen adolescents who 
had attempted to conceive 62% reported primary infertility. Weight loss and use of 
oral contraceptive pill in adolescence may improve menstrual function and prevent 
primary infertility. 
In our study total cholesterol, LDL cholesterol, and triglyceride levels were 
significantly higher in the adult group compared to the adolescents. Some form of 
dylipidaemia was present in in 59% of the adolescents in our study and this is higher 
than rates reported by Huang et al in South China where dyslipidaemia was present 
in 22.7% of adolescents with PCOS.45 The lipid abnormalities in our study population 
tended to worsen with age, and in the group of older women only 13% had no lipid 
abnormalities compared with 41% of the adolescent group.  
The prevalence of hypertension amongst the older women (28%) in our study was 
higher than the prevalence of hypertension in all South African women which is 
reported to be 21%.49 This is higher than figures reported in a Brazilian study by 
Barcellos et al which revealed a hypertension prevalence of 20.3% amongst women 
with PCOS.51 
Amongst the adolescent group the prevalence of hypertension was 8% which is 
lower than that reported by Bradshaw et al amongst non PCOS overweight South 
African adolescents (11%). 50 These findings suggest that hypertension is not a 
common finding in PCOS adolescents and is more common in the older women 
suggesting that it develops over a passage of time. 
The prevalence of metabolic syndrome amongst the adolescent group was 12.7% 
when applying both the adult criteria and the adjusted criteria for diagnosis in 
adolescence. This number is lower than the finding reported by Rossi et al in 
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Rochester, USA who found that when the adolescent criteria was used 53% of the 
adolescents in their study population had metabolic syndrome but by the adult 
criteria only 26% of the PCOS adolescents met the diagnostic criteria for metabolic 
syndrome.47 Our findings were similar to those reported in Pennsylvania, USA by 
Roe et al who found that 10.8% of their adolescents fulfilled the criteria for metabolic 
syndrome. 19 Our results were in keeping with a study done in Western Australia by 
Hart et al where the criteria for metabolic syndrome were met in 11.8% of the 
adolescent girls with PCOS, this was influenced by BMI and where the BMI was 
raised 53% of adolescents in the study met the criteria for metabolic syndrome.46 
This highlights the importance of early intervention and lifestyle changes including 
weight loss. 
Among the older women in our study population only 38% satisfied the criteria and 
were classified as having metabolic syndrome. This is similar to the findings by 
Essah et al in Virginia, USA suggesting that metabolic syndrome in adults with 
PCOS is approximately 40%. 48 This is higher than the rates of metabolic syndrome 
reported among the adolescents which shows that the disease progresses with age. 
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Conclusion: 
The results of our study clearly demonstrate that the adolescents share many of the 
clinical and metabolic abnormalities as the adult population. In this study 
abnormalities progress over the years and the metabolic disorders, especially 
dyslipidaemia and hypertension, infertility and metabolic syndrome were more 
pronounced in the older women. 
PCOS is chronic lifelong condition requiring long term management. Early diagnosis 
and a multidisciplinary approach to treatment of PCOS and an increased awareness 
of the need for assessment of co-morbidities such as hypertension, dyslipidaemia 
and IGT, is required to allow for earlier detection and treatment in adolescence and 
then continued into adult years and this may improve the prognosis and have long 
term health benefits. 
If diagnosed early and managed properly with lifestyle modification and 
pharmacological treatments, the onset of type 2 diabetes mellitus and the risk of 
coronary artery disease may be delayed or prevented. 
 
 
 
P a g e  | 43 
 
 
 
 
References: 
1. The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop 
Group. Revised 2003 consensus on diagnostic criteria and long-term health risks 
related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1): 41-47. 
2. Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Practice 
& Research Clil Endocrinol & Metabol 2006;20(2):311-330. 
3. O'Brien R, Emans S. Polycystic ovary syndrome in adolescents. J Pediatr Adolesc 
Gynecol. 2008;21(3):119-128 
4. Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose 
tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 
1999;22(1):141-146. 
5. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol & Metabol 
Clinics of North America. 1999;28(2):341-359. 
6. Du Toit M, Siebert T. Polycystic ovary syndrome (PCOS)–the long-term 
implications. S Afr J Obstet Gynaecol. 2009;15(2): 48-53. 
P a g e  | 44 
 
7. Talbott E, Guzick D, Clerici A et al. Coronary heart disease risk factors in women 
with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15(7):821-826. 
8. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial 
carcinoma. Lancet. 2003;361(9371):1810-1812. 
9. Norman, RJ. Consensus on infertility treatment related to polycystic ovary 
syndrome. Hum Reprod. 2008; 23(3):462-477 
10. Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: A 
review. Obstet and Gynaecol Survey. 2006;61(11):723-732. 
11. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary 
syndrome. Ann Int Med. 2000;132(12):989-993. 
12. Balen A, Laven J, Tan S et al. Ultrasound assessment of the polycystic ovary: 
international consensus definitions. Hum Reprod. 2003; 9 (6): 505-514 
13. Fingert SB, Shah B, Kessler M et al. Evaluation of adolescents for polycystic 
ovary syndrome in an urban population. J Clin Research Paediatr Endocrinol. 
2009;1(4):188-193. 
14. Hickey M, Doherty DA, Atkinson H et al. Clinical, ultrasound and biochemical 
features of polycystic ovary syndrome in adolescents: Implications for diagnosis. 
Hum Reprod. 2011;26(6):1469-1477. 
15. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome 
in adolescents. Obstet & Gynaecol. 2010;203(3):201-205. 
P a g e  | 45 
 
16. Glueck CJ, Morrison JA, Friedman LA et al. Obesity, free testosterone, and 
cardiovascular risk factors in adolescents with polycystic ovary syndrome and 
regularly cycling adolescents. Metabolism. 2006;55(4):508-514. 
17. Pasquali R, Casimirri F, Atenuccil D. Relationship between onset of obesity and 
onset of oligomenorrhea or amenorrhea in females with obesity and polycystic 
ovaries.  In: Adolescence in females.Year Book Medical Publications, Chicago, USA. 
1985:363-365. 
18. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary 
syndrome have an increased risk of the metabolic syndrome associated with 
increasing androgen levels independent of obesity and insulin resistance. J Clin 
Endocrinol & Metab. 2006;91(2):492-497. 
19. Weiss R, Dziura J, Burger TS et al. Obesity and the metabolic syndrome in 
children and adolescents. N Engl J Med. 2004;350(23):2362-2374. 
20. Roe AH, Prochaska E, Smith M et al. Using the androgen excess-PCOS society 
criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in 
adolescents. J Pediatr. 2013; 162(5): 937-941. 
21. Moran L, Teede H. Metabolic features of the reproductive phenotypes of 
polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477-488. 
22. Silfen ME, Denburg MR, Manibo AM et al. Early endocrine, metabolic, and 
sonographic characteristics of polycystic ovary syndrome (PCOS): Comparison 
between nonobese and obese adolescents. J Clin Endocrinol & Metab. 
2003;88(10):4682-4688. 
P a g e  | 46 
 
23. Nur MM, Newman IM, Siqueira LM. Glucose metabolism in overweight Hispanic 
adolescents with and without polycystic ovary syndrome. Pediatrics. 
2009;124(3):496-502. 
24. Salley KE, Wickham EP, Cheang KI et al. POSITION STATEMENT: Glucose 
intolerance in polycystic ovary syndrome—a position statement of the Androgen 
Excess Society. J Clin Endocrinol & Metab. 2007;92(12):4546-4556. 
25. Stanley T, Misra M. Polycystic ovary syndrome in obese adolescents. Curr Opin 
Endocrinol, Diabet and Obesity. 2008;15(1):30-36. 
26. Norman RJ, Masters L, Milner CR et al. Relative risk of conversion from 
normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes 
mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16(9):1995-1998. 
27. The Amsterdam ESHRE/ASRM-Spnsored 3rd PCOS Consensus Workshop 
group. Consensus on women’s health aspects of polycystic ovary syndrome 
(PCOS). Hum Reprod. 2011;27(1): 14-24. 
28. Jones GL, Hall JM, Lashen L et al. Health‐Related quality of life among 
adolescents with polycystic ovary syndrome. J Obstet, Gynecol, Neonatal Nurs. 
2011;40(5):577-588. 
29. Homburg R,Lambalk CB. Polycystic ovary syndrome in adolescence a 
therapeutic conundrum. Hum Reprod. 2004;19(5):1039-1042. 
30. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual 
function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 
2011;24(3):161-165. 
P a g e  | 47 
 
31. Lifshitz F, Hall JG. Reduction in the Incidence of type II Diabetes with Lifestyle 
Intervention or Metformin. J Pediatr. 2002;109:45-60. 
32. Brown J, Farquhar C, Lee O et al. Spironolactone versus placebo or in 
combination with steroids for hirsutism and/or acne (review). Cochrane Database 
Systematic Review.2003; 4: CD00019:1-15. 
33. Van der Spuy Z, Le Roux P, Matjila M. Cyproterone acetate for hirsutism. 
Cochrane Database Syst Rev. 2003;4(CD001125):1-28. 
34. Franks S. Polycystic ovary syndrome in adolescents. Int Journal Obesity. 
2008;32: 1035-1041. 
35. Balen AH, Conway GS, Kaltsas G et al. Polycystic ovarian syndrome: the 
spectrum of the disorder in 1741 patients. Hum Reprod.1995;10(8): 2107-11. 
36. Elting MW, Korsen TJ, Schoenmaker J. Obesity rather than menstrual cycle 
pattern or follicular cohort size, determines hyperinsulinaemia, dyslipidaemia and 
hypertension in ageing women with PCOS. Clin Endocrinol .2001; 55(6): 767-776. 
37. Dunaif  A, Segal K, Shelly D et al. Evidence for distinctive and intrinsic defects in 
insulin action in Polycystic Ovary Syndrome. Diabetes.1992; 41: 1258-1262. 
38. Pasquali R, Antenucci D, Casimirri F et al. Clinical and Hormonal characteristics 
of obese hyperandrogenic women before and after weight loss. J Clin Endocrinol 
Metab. 1989; 68 (1): 173-176. 
P a g e  | 48 
 
39. Clark  AM, Thornley B, Tomilinson L et al. Weight loss in obese infertile women 
results in improvement in reproductive outcome for all forms of fertility treatment. 
Hum Reprod. 1998; 13 (6):1502–1505. 
40. Azziz  R, Carmina E, Dewailly D et al. Androgen Excess Society. Position 
statement: criteria for defining polycystic ovary syndrome as a predominantly 
hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin 
Endocrinol Metab. 2006; 91: 4237-4245. 
41. Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose 
tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 
1999; 22(1): 141-146 
42. Begum, F. Clinical and Hormonal Profile of Polycystic Ovary Syndrome. South 
Asian Fed Obstet Gynaecol. 2009; 1 (2): 22-25 
43. Sharquie KE, AL- Bayatti, A, AL-Bahar A & Al-Zaidi, Q. Acanthosis Nigricans as 
skin manifestation of PCOS in primary infertile females. Middle East J Fertil Soc. 
2004; 9 (2): 136-139 
44. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in 
adolescents with Polycystic ovary syndrome who were treated with two forms of 
combined oral contraceptives. Fertil Steril. 2002; 77(5): 919-927 
45. Huang J, Renmin N, Xioli C et al. Metabolic abnormalities in adolescents with 
Polycystic ovary syndrome in South China. Reprod Bio Endocrinol. 2010; 8: 142-
149. 
P a g e  | 49 
 
46. Hart R, Dohert D, Mori T et al. Extent of metabolic risk in adolescent girls with 
features of polycystic ovary syndrome. Fertil Steril. 2011; 95 (7): 2347-2353. 
47. Rossi B, Sukalich S, Droz J et al. Prevalence of Metabolic Syndrome and related 
characteristics in obese adolescents with and without Polycystic Ovary Syndrome. J 
Clin Endocrinol Metabol. 2008; 93 (12): 4780-4786. 
48. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. 
Clin Obstet Gynaecol. 2007; 50 (1): 205-225. 
49. Steyn K, Gaziano T, Thomas A et al. Hypertension in South African adults: 
results from the demographic and health survey. 1998; 19 (10) 1717-1725. 
50. Bradshaw, Steyn K, Levitt N & Nojilana B. Non-communicable diseases- the race 
against time. Parow, South Africa: Medical Research Council (2010).  
51.Barcellos C, Rocha M, Hayashida S et al. Impact of body mass index on blood 
pressure levels in patients with polycystic ovary syndrome. Arq Bras Endocrinol 
Metabol. 2007; 51(7): 1104-1109 
52. Wild R, Vesely S, Whitsett T et al. Ferriman Gallwey Self Scoring 1: Performance 
assessment in women with PCOS. J Clin Endocrinol Metabol. 2005; 90(1): 4112-
4114 
53. Azziz R, Carmina E, Dewailly D et al. The Androgen Excess and PCOS Society 
criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 
2009; 91 (2): 456-488 
P a g e  | 50 
 
54.Lewy V, Danadian K, Witchel S & Arslanian S. Early metabolic abnormalities in 
adolescent girls with polycystic ovarian syndrome. J Paed. 2001;138 (1): 38-44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 51 
 
 
 
 
